Products from BPS Bioscience require a minimum order value above 400€
Applications: This kit is useful for detection of anti SARS-CoV-2 Spike IgG in human serum.
Background: As the viral load increases in the infected individual prior to the onset of symptoms, the individual may unknowingly be able to actively spread the infection during this presymptomatic phase. Once the immune system recognizes the infection, IgM is generated against the virus initially, followed by a second response leading to the production of higher affinity IgG molecules targeting the SARS-CoV-2 virus. IgG antibodies to SARS-CoV-2 generally become detectable beginning 10 - 14 days following infection but may occur later. The presence of IgG antibodies, following previously negative testing defines IgG antibody seroconversion following SARS-CoV-2 infection. False positive results for IgG antibodies may occur due to cross-reactivity from pre-existing antibodies or other possible causes. This assay kit is not intended for clinical diagnostic use.
Description: The SARS-CoV-2 IgG detection kit is designed for qualitative detection of human IgG antibodies in serum collected from individuals suspected of prior infection with the virus that causes COVID-19. This fast and simple ELISA uses the trimeric form of the SARS-CoV-2 Spike protein (BPS Bioscience #100728) to identify IgG antibodies that indicate a previous infection with SARS-CoV-2. The Spike protein is expressed on the viral membrane as a trimer, which means this kit measures IgG antibodies in a more physiologically relevant context than many other commercially available ELISA kits.
Storage Stability: Up to 6 months from date of receipt, when stored as recommended.
Supplied As: The SARS-CoV-2 IgG Detection Kit comes in a convenient 96-well format, with purified trimeric SARS-CoV-2 Spike protein and an HRP-conjugated anti-human Fc antibody for 100 binding reactions.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: Long, Q.-X., et al. 2020. Antibody responses to SARS-CoV-2 in patients withCOVID-19. Nat. Med. (in press). https://doi.org/10.1038/s41591-020-0897-1
English
Deutsch
